MD Anderson and Summit Therapeutics announced a strategic five-year collaboration to accelerate the development of ivonescimab, a novel PD-1/VEGF bispecific antibody.
MD Anderson and Summit Therapeutics announced a strategic five-year collaboration to accelerate the development of ivonescimab, a novel PD-1/VEGF bispecific antibody.